In May, Chinese regulators approved Eli Lilly and Company’s Mounjaro (tirzapatide) for type 2 diabetes. On 21 July, the major US drug maker announced on social media network WeChat the approval of the GLP-1/GIP agonist in China for weight loss, as Zepbound.
Mounjaro Approval Takes Global Obesity Battle To China
New Policies Also Released
The global battle of the blockbuster obesity drugs appears set to come to China with the approval of Lilly's Mounjaro, although domestic competitors are fast catching up.
